Onco-Hu® Models are a robust platform for efficacy testing of novel immunotherapies targeting various immune cells, including T cells, myeloid cells, and NK cells.
人源化NSGTM, NSG TM-SGM3，NSG TM-IL15均可现货供应
Our collections of humanized NSG™ and NSG™-SGM3 mice generate functional human immune systems with expansive capabilities. Mouse models with humanized immune systems represent ground-breaking platforms to evaluate compounds to treat a variety of human diseases, from cancer and infectious diseases to allergies, inflammation and Graft versus Host Disease.
The hosts for hu-CD34 and hu-PBMC models are NOD scid gamma (NSG™) mouse, developed by JAX Professor Lenny Shultz and the NSG™-SGM3 strain, shown to support greater engraftment of human hematopoietic stem cells (hu-CD34+ cells) than all other strains.
Humanized CD34+ mice (hu-CD34) are a robust in vivo platform for analyzing the safety and effectiveness of potential new drugs to modulate the immune system. Hu-CD34 mice are supreme in vivo models for long-term studies in the fields of immuno-oncology, infectious disease, and graft versus host disease.
Models engrafted with cord blood-derived hematopoietic stem cells (HSC) develop a functional human immune system and display robust T-cell maturation and T-cell dependent inflammatory responses. Large cohorts of humanized CD34+ NSG™ and NSG™-SGM3 mice are available for immediate delivery or to enroll in JAX drug efficacy testing services.
Humanized PBMC (hu-PBMC) mice are used as in vivo models to study and evaluate compounds for infectious diseases and graft rejection research. Hu-PBMC models have the fastest engraftment rate using adult peripheral blood mononuclear cells and enable short-term studies requiring a strong effector and memory T cell and NK cell function.